Literature DB >> 29694819

Prenatal Correction of X-Linked Hypohidrotic Ectodermal Dysplasia.

Holm Schneider1, Florian Faschingbauer1, Sonia Schuepbach-Mallepell1, Iris Körber1, Sigrun Wohlfart1, Angela Dick1, Mandy Wahlbuhl1, Christine Kowalczyk-Quintas1, Michele Vigolo1, Neil Kirby1, Corinna Tannert1, Oliver Rompel1, Wolfgang Rascher1, Matthias W Beckmann1, Pascal Schneider1.   

Abstract

Genetic deficiency of ectodysplasin A (EDA) causes X-linked hypohidrotic ectodermal dysplasia (XLHED), in which the development of sweat glands is irreversibly impaired, an condition that can lead to life-threatening hyperthermia. We observed normal development of mouse fetuses with Eda mutations after they had been exposed in utero to a recombinant protein that includes the receptor-binding domain of EDA. We administered this protein intraamniotically to two affected human twins at gestational weeks 26 and 31 and to a single affected human fetus at gestational week 26; the infants, born in week 33 (twins) and week 39 (singleton), were able to sweat normally, and XLHED-related illness had not developed by 14 to 22 months of age. (Funded by Edimer Pharmaceuticals and others.).

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29694819     DOI: 10.1056/NEJMoa1714322

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  32 in total

1.  Molecular Diagnostics and In Utero Therapeutics for Orofacial Clefts.

Authors:  J D Oliver; E C Turner; L R Halpern; S Jia; P Schneider; R N D'Souza
Journal:  J Dent Res       Date:  2020-07-01       Impact factor: 6.116

Review 2.  Ectodermal dysplasias: Classification and organization by phenotype, genotype and molecular pathway.

Authors:  John Timothy Wright; Mary Fete; Holm Schneider; Madelaine Zinser; Maranke I Koster; Angus J Clarke; Smail Hadj-Rabia; Gianluca Tadini; Nina Pagnan; Atila F Visinoni; Birgitta Bergendal; Becky Abbott; Timothy Fete; Clark Stanford; Clayton Butcher; Rena N D'Souza; Virginia P Sybert; Maria I Morasso
Journal:  Am J Med Genet A       Date:  2019-01-31       Impact factor: 2.802

3.  In Utero Gene Therapy Consensus Statement from the IFeTIS.

Authors:  Graça Almeida-Porada; Simon N Waddington; Jerry K Y Chan; William H Peranteau; Tippi MacKenzie; Christopher D Porada
Journal:  Mol Ther       Date:  2019-03-02       Impact factor: 11.454

Review 4.  Fetal and Maternal Safety Considerations for In Utero Therapy Clinical Trials: iFeTiS Consensus Statement.

Authors:  Rachel Sagar; Graça Almeida-Porada; Karin Blakemore; Jerry K Y Chan; Mahesh Choolani; Cecilia Götherström; Agnes Jaulent; Tippi C MacKenzie; Citra Mattar; Christopher D Porada; William H Peranteau; Holm Schneider; Steven W Shaw; Simon N Waddington; Magnus Westgren; Anna L David
Journal:  Mol Ther       Date:  2020-10-16       Impact factor: 11.454

5.  The Era of the Genome and Dental Medicine.

Authors:  K Divaris
Journal:  J Dent Res       Date:  2019-08       Impact factor: 6.116

6.  Prenatal Treatment of X-Linked Hypohidrotic Ectodermal Dysplasia using Recombinant Ectodysplasin in a Canine Model.

Authors:  Carol A Margolis; Pascal Schneider; Kenneth Huttner; Neil Kirby; Timothy P Houser; Lee Wildman; Gary L Grove; Holm Schneider; Margret L Casal
Journal:  J Pharmacol Exp Ther       Date:  2019-04-18       Impact factor: 4.030

7.  Sweating ability of patients with p63-associated syndromes.

Authors:  Paul Ferstl; Sigrun Wohlfart; Holm Schneider
Journal:  Eur J Pediatr       Date:  2018-08-07       Impact factor: 3.183

Review 8.  The current and future impact of genome-wide sequencing on fetal precision medicine.

Authors:  Riwa Sabbagh; Ignatia B Van den Veyver
Journal:  Hum Genet       Date:  2019-11-21       Impact factor: 4.132

9.  Lysosomal storage disease spectrum in nonimmune hydrops fetalis: a retrospective case control study.

Authors:  Huda B Al-Kouatly; Laura Felder; Mona M Makhamreh; Stephanie L Kass; Neeta L Vora; Vincenzo Berghella; Seth Berger; David A Wenger; Paola Luzi
Journal:  Prenat Diagn       Date:  2020-03-20       Impact factor: 3.050

Review 10.  Fetal gene therapy and pharmacotherapy to treat congenital hearing loss and vestibular dysfunction.

Authors:  Michelle L Hastings; John V Brigande
Journal:  Hear Res       Date:  2020-03-05       Impact factor: 3.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.